Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kymera receives FDA fast track designation for KT-333
KT-333 is intended for the treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma. Credit: Nephron/commons.wikimedia.org.
KT-333 is intended for the treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma. Credit: Nephron/commons.wikimedia.org.